There are 2789 resources available
714P - Prognostic factors in stage I seminoma: Data from the phase III, randomised TRial of Imaging and Surveillance in Seminoma Testis (TRISST)
Presenter: Elizabeth James
Session: ePoster Display
715P - Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program
Presenter: Damien Pouessel
Session: ePoster Display
691P - Effect of NANOGNB mutations on DNA damage response and efficacy of immune checkpoint inhibitors in advanced renal clear cell carcinoma
Presenter: Zhiwen Luo
Session: ePoster Display
Resources:
Abstract
692P - Characterization of the tumor immune microenvironment in early-stage clear cell renal cell carcinoma (ccRCC): Prognostic value of an M0-macrophage enriched subtype
Presenter: Mark Farha
Session: ePoster Display
718TiP - KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)
Presenter: Shahrokh F. Shariat
Session: ePoster Display
696P - Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)
Presenter: Sara Elena Rebuzzi
Session: ePoster Display
591P - A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC)
Presenter: Rahul Aggarwal
Session: ePoster Display
592P - Bipolar androgen therapy (BAT) plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Michael Schweizer
Session: ePoster Display